← Back to patent-cliff list
JAB-3068
Tier C — Watch / tradeJAB-3068
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SHP2
Indications (approved)：Non-small cell lung cancer, Solid tumour, 食管鳞状细胞癌, Head and neck squamous cell carcinoma, Lymphoma, Oesophageal cancer, Head and neck cancer, Adenoid cystic carcinoma
Regional status
US
Phase I
2018-04-23
EU
-
China
Phase II
2018-11-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of JAB-3068?
Approved indications include: Non-small cell lung cancer, Solid tumour, 食管鳞状细胞癌, Head and neck squamous cell carcinoma, Lymphoma, Oesophageal cancer, Head and neck cancer, Adenoid cystic carcinoma.
When does the JAB-3068 patent expire?
No public expiry year is available for JAB-3068 yet; this page updates once verified.
How do I get a quote for JAB-3068 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08